Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Research Article Volume 7 Issue 11

Chemo-metric Assisted UV - Spectrophotometric Methods for the Estimation of Imatinib Mesylate-An Anti Cancer Drug

Lakshman Kumar Earle and Mukthinuthalapati Mathrusri Annapurna*

Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM (Deemed to be) University, Visakhapatnam, AP, India

*Corresponding Author:Mukthinuthalapati Mathrusri Annapurna, Department of Pharmaceutical Analysis, GITAM School of Pharmacy, GITAM (Deemed to be) University, Visakhapatnam, AP, India.

Received: October 25, 2023; Published: October 31, 2023

Abstract

Imatinib mesylate is an anti-cancer agent used for the treatment of Myeloid leukemia. Three chemometric assisted UV-spectrophotometric methods have been developed for the estimation of Imatinib mesylate tablet formulations. A double beam UV-VIS spectrophotometer (Shimadzu Model No. UV-1800) was used for the study. Imatinib mesylate has shown linearity over the concentration range 1-30, 0.1-30 and 0.5-30 μg/mL in phosphate buffer (pH 8.0), borate buffer (pH 9.0) and in 0.1N hydrochloric acid solution in zero order as well as first order derivative spectrophotometric techniques. The proposed methods were validated as per ICH guidelines.

Keywords: Imatinib Mesylate; Derivative Spectroscopy; ICH Guidelines; Validation

References

  1. Weisberg E., et al. “Second generation inhibitors of BCR-ABL for the treatment of Imatinib-resistant chronic myeloid leukaemia”. Nature Reviews Cancer5 (2007): 345-356.v
  2. Vijaya K., et al. “Validation of UV spectrophotometric and HPLC methods for quantitative determination of Imatinib in bulk and pharmaceutical dosage form”. Asian Journal of Research in Chemistry3 (2018): 555-562.
  3. Widmer N., et al. “Determination of Imatinib in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection”. Journal of Chromatography B2 (2004): 285-292.
  4. Adeagbo BA., et al. “Simple HPLC-UV method for pharmacokinetic studies of Imatinib in the presence of common antimalaria agents”. Journal of Liquid Chromatography & Related Technologies12 (2015): 1194-1198.
  5. Ka Liong Tana., et al. “Method development and validation for the simultaneous determination of Imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection”. Journal of Chromatography B30 (2011): 3583-3591.
  6. Sathwik G., et al. “Analytical method development and validation of solid dosage form of antineoplastic drug Imatinib mesylate by RP HPLC”. International Journal of Pharma Sciences and Research4 (2015): 697-705.
  7. Ivanovic D., et al. “Reversed-phase liquid chromatography analysis of Imatinib mesylate and impurity product in Glivec capsules”. Journal of Chromatography B1-2 (2004): 253-258.
  8. Kuna., et al. “RP-HPLC method development and validation of imatinib mesylate in tablet dosage form”. International Journal of Pharmacy and Pharmaceutical Sciences5 (2011): 162-165.
  9. Oostendorp., et al. “Determination of Imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion‐pairing reversed‐phase high‐performance liquid chromatography”. Biomedical Chromatography7 (2007): 747-754.
  10. Rosasco., et al. “Validation of an HPLC method for the determination of Imatinib mesylate in pharmaceutical dosage”. Journal of Liquid Chromatography and Related Technologies20 (2005): 3283-3292.
  11. Thirumurthy., et al. “Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of Imatinib in biological samples”. Journal of Chromatography B2 (2004): 431-434.
  12. Titier., et al. “Quantification of Imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry”. Therapeutic Drug Monitoring5 (2005): 634-640.
  13. Parise., et al. “Liquid chromatographic-mass spectrometric assay for quantitation of Imatinib and its main metabolite (CGP 74588) in plasma”. Journal of Chromatography B1-2 (2003): 39-44.
  14. Solassol I., et al. “Liquid chromatography‐electrospray mass spectrometry determination of Imatinib and its main metabolite, N‐desmethyl‐Imatinib in human plasma”. Journal of Liquid Chromatography and Related Technologies 20 (2006): 2957-2974.
  15. Yang., et al. “Rapid determination of Imatinib in human plasma by liquid chromatography-tandem mass spectrometry: Application to a pharmacokinetic study”. Bulletin of the Korean Chemical Society8 (2013): 2425-2430.
  16. Zhang., et al. “LC-MS-MS determination of Imatinib and N-desmethyl imatinib in human plasma”. Journal of Chromatographic Science 4 (2014): 344-350.
  17. Akiful Haque M., et al. “Development of UV-spectrophotometric method for the determination of Imatinib mesylate (ITM) in bulk and formulation”. International Journal of Pharma Research and Health Sciences2 (2016): 1130-1135.
  18. Swetha R., et al. “Stability indicating UV-Spectrophotometric method development and its validation for the determination of Imatinib mesylate in bulk and formulation”. Asian Journal of Pharmaceutical Analysis2 (2022): 83-86.
  19. Rajan V., et al. “Derivative UV spectrophotometric method for validation of Imatinib mesylate in bulk and pharmaceutical dosage form”. Asian Journal of Research Chemistry5 (2019): 253-257.
  20. Bende G., et al. “UV-spectrophotometric determination of Imatinib mesylate and its application in solubility studies”. An International Journal of Pharmaceutical Sciences9 (2008): 641-645.
  21. Ajith kumar P and Anton smith A. “Development of analytical method for Imatinib mesylate by ultraviolet spectroscopy”. Asian Journal of Pharmaceutical and Clinical Research1 (2020): 180-183.
  22. Karthikeyan R., et al. “New spectrophotometric methods for the determination of Imatinib in bulk drug and in pharmaceutical formulations”. Research Journal Pharmacy and Technology3 (2009): 578-581.
  23. Karim SSE., et al. “Spectrophotometric determination of Imatinib mesylate using charge transfer complexs in pure form and pharmaceutical formulation”. Chemical Rapid Communications3 (2014): 55-63.
  24. Rele RV and Prathamesh PT. “UV spectrophotometric estimation of Imatinib mesylate by area under curve methods in bulk and pharmaceutical dosage form”. Asian Journal of Research in Chemistry4 (2019): 213-216.
  25. Sasikala M., et al. “Quantitative determination of drugs by using Cerium (IV) and indigocaramine couple: A spectrophotometric study”. Journal of Chemistry and Chemical Sciences8 (2015): 463-475.

Citation

Citation: Lakshman Kumar Earle and Mukthinuthalapati Mathrusri Annapurna. “Chemo-metric Assisted UV - Spectrophotometric Methods for the Estimation of Imatinib Mesylate-An Anti Cancer Drug".Acta Scientific Pharmaceutical Sciences 7.11 (2023): 53-58.

Copyright

Copyright: © 2023 Lakshman Kumar Earle and Mukthinuthalapati Mathrusri Annapurna. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue".
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US